News Related to Gastroenteropancreatic Neuroendocrine Tumors

Related coverage linked through entity extraction aliases.

FDA Accepts Camurus NDA Resubmission for Oclaiz in Acromegaly, Sets December 2026 PDUFA Date

Jul 17, 2026

The FDA accepted Camurus' NDA resubmission for Oclaiz in acromegaly, setting a December 2026 PDUFA date. The filing follows a June 2026 Complete Response Letter related to third-party manufacturing, with no safety or efficacy issues. Oclaiz is a once-monthly subcutaneous octreotide already approved in the EU as Oczyesa.

Bristol Myers Squibb Growth Portfolio Offsets Legacy Drug Declines in 2025

Mar 03, 2026

Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.